Roche company Genentech announced that the Phase III IMvigor010 trial of Tecentriq as a post-surgery monotherapy did not hit the primary endpoint in muscle-invasive urothelial cancer (MIUC).
Brain-disease focused Cerevance and Takeda Pharmaceutical forged a research collaboration to tackle gastrointestinal disorders that have their roots in the central nervous system.
The new global pharmaceutical company combines Mylan N.V. with Upjohn, Pfizer Inc.’s off-patent branded and generic established medicines business.
Novartis, Amgen and the Banner Alzheimer’s Institute announced they are halting two pivotal Phase II/III clinical trials in the Alzheimer’s Prevention Initiative Generation Program.
A new discovery at the Feinstein Institutes for Medical Research could have implications in the way diabetes is treated in the future.
The U.S. FDA gave Alexion Pharmaceuticals a thumbs-up for Soliris (eculizumab) to treat neuromyelitis optica spectrum disorder in adults that express a specific biomarker.
Newron must delay a trial of the Swiss-listed drugmaker’s prospective schizophrenia medicine evenamide after the U.S. FDA raised concerns about CNS events that emerged in rats and dogs.
Wave Life Sciences Ltd. announced the formation of a global strategic collaboration with Takeda Pharmaceutical Company Ltd. to discover, develop and commercialize nucleic acid therapies for disorders of the central nervous system.
The good news … is that innovation is addressing diseases with high-unmet need such as oncology, autoimmune diseases, and central nervous system (CNS) disorders. But, there is a complicating factor in the economic story: the patient population benefiting from launch brands is becoming smaller.
11 billion euro R&D programme through 2020, with 5 billion euro dedicated to pre-clinical R&D and 1.5 billion euro planned for cooperation with external partners New partnerships with the […]
